The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Shingrix (Zostavax) Market Between 2026 And 2030?
Historical growth was propelled by a heightened understanding of shingles complications, the expanding global elderly population, previous constraints with live attenuated vaccines, wider immunization directives for older adults, and growing physician recommendation rates.
The anticipated expansion during the projection period is primarily driven by more ambitious targets for adult vaccination coverage, increased healthcare spending on preventive care, the broadening of recombinant vaccine development pipelines, growing government-supported immunization initiatives, and an increasing focus on mitigating the burden of post-herpetic neuralgia. Concurrently, major trends expected in the forecast period include a greater adoption of recombinant vaccine platforms, an elevated focus on adult immunization programs, rising demand for durable shingles protection, the expansion of cold-chain optimized vaccine distribution networks, and an enhanced emphasis on vaccine safety and efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
Which Significant Factors Are Encouraging Growth In The Shingrix (Zostavax) Market?
The increasing embrace of vaccination is projected to drive the expansion of the shingrix (zostavax) market. Vaccination involves giving a vaccine to encourage the body’s immune system to identify and combat particular disease-causing agents. This rising acceptance of vaccination stems from heightened understanding of its efficacy in preventing illnesses, decreasing the burden of disease, and the creation of secure and readily available vaccines. Furthermore, public health efforts, better healthcare facilities, and worldwide immunization programs also play a role in its broad adoption. Shingrix (Zostavax) is valuable for vaccination as it offers robust defense against shingles and related issues. It proves especially advantageous for individuals over 50 years of age, substantially lowering the likelihood of shingles recurring and of developing post-herpetic neuralgia. As an illustration, a study published in May 2024 by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, indicated that shingles vaccinations covered by Medicare Part D saw a 46% rise in the year subsequent to the IRA policy’s introduction in January 2023. Consequently, the expanding uptake of vaccination is fueling the growth of the shingrix (zostavax) market.
How Is The Shingrix (Zostavax) Market Examined Through Segment Analysis?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
Which Trends Are Supporting The Evolution Of The Shingrix (Zostavax) Market?
Leading companies operating in the shingrix (zostavax) market are concentrating on developing innovative solutions, such as non-live, recombinant subunit adjuvanted vaccines, to address the increasing demand for safer and more effective immunization. This demand is particularly influenced by age-related immune decline and the necessity for options in immunocompromised populations. A non-live, recombinant subunit adjuvanted vaccine includes specific protein components (antigens) of a pathogen, combined with an adjuvant to boost the immune response, contrasting with traditional live-attenuated vaccines that utilize weakened forms of the whole virus. For example, in 2023, GSK plc, a UK-based biopharmaceutical firm, introduced Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, administered intramuscularly in two doses, and is composed of the glycoprotein E antigen along with GSK’s proprietary AS01B adjuvant system. Shingrix stimulates a powerful and enduring immune response, counteracting the reduction in immunity in older adults, and delivers very high efficacy (up to ~97%).
Who Are The Key Market Participants In The Shingrix (Zostavax) Market?
Major companies operating in the shingrix (zostavax) market are GSK plc
Access The Complete Shingrix (Zostavax) Market Report:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
Which Region Has The Strongest Presence In The Shingrix (Zostavax) Market?
North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model